PRAXIS PRECISION MEDICINES, INC. Sale of Stock, Consideration Received on Transaction
PRAXIS PRECISION MEDICINES, INC. (PRAX) reported Sale of Stock, Consideration Received on Transaction of $7.00 million for the 2-month period ending 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2022-02-28
- 2021-12-31: Sale of Stock, Consideration Received on Transaction 2 month $7.00M.
| Period end | Sale of Stock, Consideration Received on Transaction 2 month |
|---|---|
| 2021-12-31 | $7.00M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |